Pfizer Inc PFE has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor. What Happened: The lawsuit, filed by wholesale drug distributors, accused Pfizer of ...

When patents expire on profitable brand-name prescription drugs, patients and their insurance companies usually both catch a break on the price as generic manufacturers move in with cheaper versions ...

Indianapolis-based WellPoint Inc. is in a tussle with the nation’s largest drug maker over the nation’s top-selling drug. New York-based Pfizer Inc., facing the loss of billions in sales of its ...

NEW YORK — Pfizer Inc. won a crucial court ruling Friday that will allow it to exclusively sell the top-selling drug worldwide, the cholesterol-lowering drug Lipitor, until 2011. Shares of Pfizer, the ...

KALAMAZOO, MI – For the last few years, investors, employees and communities that have Pfizer as a major employer have wondered how it would fare as it blockbuster drug loose patent protection and ...

My husband's doctor cut back his Lipitor from 80 milligrams a day to 40 milligrams. My husband worries about his liver because the doctor doesn't check it very often, but he's afraid to quit taking ...

Pfizer Inc (NYSE:PFE) said Chief Executive Ian Read's compensation jumped more than 40 percent last year to $25 million as he steered a steady course for the world's biggest drugmaker while its ...

Pfizer Inc. has lost a preliminary bid to gain reissuance of one of the U.S. patents protecting its Lipitor cholesterol medicine. Should the ruling stand, Pfizer would face U.S. generic competition to ...

NEW YORK (Reuters) - It may take a breakthrough treatment for Alzheimer's disease to match the $130 billion lifetime sales record of Pfizer's Lipitor, the cholesterol fighter that wrote its own ...

(Adds closing Pfizer shares) By Ransdell Pierson NEW YORK, June 18 (Reuters) - Pfizer Inc <PFE.N> said on Wednesday that Ranbaxy Laboratories Ltd <RANB.BO> can begin selling a U.S. generic form of its ...

Pfizer is interested in selling a non-prescription version of its Lipitor cholesterol drug but would likely face a battle with regulators because of safety concerns, the Wall Street Journal reported ...